Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT07396246

Comparison Between Transarterial Musculoskeletal Embolization and Platelet-Rich Plasma Injection for the Treatment of Greater Trochanteric Pain Syndrome

Led by Unidade Local de Saúde do Alto Ave, EPE · Updated on 2026-02-09

30

Participants Needed

1

Research Sites

103 weeks

Total Duration

On this page

Sponsors

U

Unidade Local de Saúde do Alto Ave, EPE

Lead Sponsor

S

Serviço de Ortopedia da ULS Alto Ave

Collaborating Sponsor

AI-Summary

What this Trial Is About

Greater Trochanteric Pain Syndrome (GTPS) is a common cause of lateral hip pain that can significantly affect daily activities and quality of life. Standard treatments include physical therapy, anti-inflammatory medications, and local injections, but many patients continue to experience persistent symptoms. This randomized controlled trial aims to compare two minimally invasive treatment options for GTPS: transarterial musculoskeletal embolization (TAME) and platelet-rich plasma (PRP) injection. Participants will be randomly assigned to receive either TAME or PRP. The main goal of the study is to evaluate which treatment is more effective in reducing pain. Secondary goals include comparing functional improvement, quality of life, and safety between the two treatments. Pain and functional outcomes will be assessed at baseline and during follow-up at 1, 3, 6, and 12 months after treatment. This study seeks to provide evidence on the effectiveness and safety of TAME compared with PRP injection for patients with Greater Trochanteric Pain Syndrome.

CONDITIONS

Official Title

Comparison Between Transarterial Musculoskeletal Embolization and Platelet-Rich Plasma Injection for the Treatment of Greater Trochanteric Pain Syndrome

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of GTPS confirmed by clinical and imaging assessments
  • Persistent symptoms despite at least 3 months of conservative treatment (e.g., physical therapy, NSAIDs)
  • Willingness to participate and provide informed consent
  • Availability for follow-up assessments at 1, 3, 6, and 12 months post-treatment
Not Eligible

You will not qualify if you...

  • Prior hip surgery or other interventions (e.g., joint replacement, prior PRP injections or embolization)
  • Severe osteoarthritis (Tonnis III)
  • Active lumbar radiculopathy with pain, numbness, or weakness in a dermatomal distribution
  • Contraindications for PRP injections (e.g., active infection, coagulopathy, antiplatelet or anticoagulation therapy)
  • Pregnancy or breastfeeding
  • Severe comorbidities that would interfere with participation
  • Active cancer or other malignancies

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Unidade Local de Saúde do Alto Ave

Guimarães, Portugal

Actively Recruiting

Loading map...

Research Team

P

Pedro M M Lopes, MD

CONTACT

J

José F V Cavalheiro, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here